A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer. Article

Full Text via DOI: 10.1200/JCO.2021.39.15_suppl.TPS3156 Web of Science: 000708120306235
International Collaboration

Cited authors

  • Bessudo A, Cohen EEW, Gutierrez R, Johnson DH, Rosenberg A, Sukari A, Stemmer SM, Weinberg BA, Reuveni H, Schickler M, Liang BC

Publication date

  • 2021

Published in

International Standard Serial Number (ISSN)

  • 0732-183X

Number of pages

  • 3


  • 39


  • 15